Can Transient Elastography Predict Fibrosis Regression in Patients with Chronic Hepatitis B During Long-Term Antiviral Therapy?

Rui Huang,Xiaomin Yan,Yong Liu,Zhaoping Zhang,Chao Wu

DOI: https://doi.org/10.1038/ajg.2017.137

2017-01-01

Abstract:Huang, Rui MD, PhD1; Yan, Xiaomin MD1; Liu, Yong PhD2; Zhang, Zhaoping MD1; Wu, Chao MD, PhD1 Author Information

What problem does this paper attempt to address?

The Value of Ultrasonic Elastographic Parameters in the Evaluation of Chronic Hepatitis B Liver Fibrosis

Kairong Ren,Xiaoxiao Xu,Pintong Huang

DOI: https://doi.org/10.1166/jmihi.2021.3549

2021-01-01

Journal of Medical Imaging and Health Informatics

Abstract:Chronic hepatitis B is one of the common chronic infectious diseases in China, which seriously endangers people’s health. Liver fibrosis is a common pathological process of chronic hepatitis B. The routine diagnosis and prediction of the degree of liver fibrosis are of great value and significance to the judgment of liver disease, clinical treatment, and the corresponding late evaluation. However, the traditional detection and treatment methods are often invasive, and the corresponding diagnosis and treatment costs are very high, which makes it difficult for the corresponding patients in clinical and practical applications to accept, and the corresponding liver tissue samples are relatively limited in technology. In this paper, based on ultrasound elastography technology, it will give full play to its advantages of real-time, non-invasive, and repeatable detection, and realize an effective method for non-invasive diagnosis of liver fibrosis. In the practical application, this paper mainly focuses on the study and analysis of the patients with hepatitis B liver fibrosis using the RTE ultrasonic elastic imaging technology. Following this, 120 patients with chronic hepatitis B were selected for the experiment, and a non-invasive diagnostic model of ultrasonic elastic imaging based on a support vector machine was proposed. The experimental results showed that the diagnostic model proposed in this paper improves the diagnostic accuracy by 5% compared with the traditional diagnostic technology, while the corresponding specificity, positive predictive value, and diagnostic advantage are improved. Therefore, as a whole, the ultrasound elastic imaging model proposed in this paper could realize the efficient diagnosis of hepatitis B liver fibrosis and is conducive to the clinical management.
A New Visual Transient Elastography Technique for Grading Liver Fibrosis in Patients with Chronic Hepatitis B.

Xinping Ren,Lu Zhang,Shujun Xia,Zhijie Chen,Wei Zhou,Ri Ji,Jianqiao Zhou,Yanyan Lin,Weiwei Zhan

DOI: https://doi.org/10.1097/ruq.0000000000000509

2020-01-01

Ultrasound Quarterly

Abstract:ABSTRACT:Liver fibrosis is evaluated to assess the prognosis and guide the treatment of chronic hepatitis B (CHB). To compare the efficiency of 2 transient elastography techniques for grading liver fibrosis in CHB: visual transient elastography (ViTE) with real-time image guidance and FibroScan (FS) with no image guidance. All of the CHB patients in this study underwent both FS and ViTE examinations. The final diagnosis was based on the histological findings of a liver biopsy. According to the severity of liver fibrosis (based on the Scheuer criteria), the area under the receiver operating characteristic curve values for diagnostic efficiency were calculated for the 2 elastography techniques. This study enrolled 227 patients (79 [39.1%] women; mean age, 45.8 ± 16.8 years). The ViTE and FS liver elasticity measurements were highly correlated with liver fibrosis stage (r = 0.852 and r = 0.813, respectively). The area under the receiver operating characteristic curve value was larger for ViTE compared with FS, with respect to differentiating liver fibrosis stage, but not significantly (P > 0.05). The ViTE and FS can be used to detect and stage liver fibrosis. ViTE, easier and quicker to perform with superior interoperator reproducibility, is a stable and reliable elastography technique that benefits from real-time visual guidance.
Longitudinal Monitoring of Liver Fibrosis Status by Transient Elastography in Chronic Hepatitis B Patients During Long-Term Entecavir Treatment.

Sheng-Di Wu,Li-Li Liu,Ji-Lin Cheng,Yun Liu,Li-Sha Cheng,Si-Qi Wang,Wei Ma,Li-Ping Chen,Yu-Jen Tseng,Ji-Yao Wang,Xi-Zhong Shen,Wei Jiang

DOI: https://doi.org/10.1007/s10238-018-0501-x

IF: 4.6

2018-01-01

Clinical and Experimental Medicine

Abstract:The correlation between improvement in longitudinal liver stiffness and fibrosis regression has not been properly evaluated during long-term antiviral therapy in chronic hepatitis B (CHB) patients. In this study, liver stiffness was serially performed by FibroScan® every 26 weeks in a prospective cohort of CHB patients receiving entecavir. Results were compared with liver biopsies at baseline and week 78. A total of 120 treatment-naïve CHB patients were analyzed, in which 54 (45%) patients had fibrosis regression at 78 weeks of antiviral therapy. Liver stiffness measurement presented as a rapid-to-slow decline pattern and decreased more significantly in patients with fibrosis regression than those without improvement in fibrosis at week 78 (− 46.4 vs. − 28.6%, P < 0.001). Multivariate analysis revealed that percentage decline of 52-week and 78-week liver stiffness from baseline was independent predictive factors for fibrosis regression (OR = 46.6, P < 0.001; OR = 17.8, P = 0.002, respectively). Moreover, percentage decline of 78-week liver stiffness was moderately predictive of fibrosis regression (AUROC = 0.694, P < 0.001), while the optimal cutoff values were different between non-cirrhosis and cirrhosis patients (38 vs. 45%). Fibrosis regression could be predicted with a high positive predictive value (96%) in non-cirrhosis patients and could be excluded with a high negative predictive value (94%) in cirrhosis patients. In conclusion, serial liver stiffness measurement could be applied for longitudinal monitoring of fibrosis status in CHB patients. Continuous decline of liver stiffness after effective antiviral treatment could partially reflect fibrosis regression at an optimal cutoff value.
AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response

Feng Liu,Yameng Sun,Dean Tai,Yayun Ren,Elaine L. K. Chng,Aileen Wee,Pierre Bedossa,Rui Huang,Jian Wang,Lai Wei,Hong You,Huiying Rao

DOI: https://doi.org/10.3390/diagnostics14161837

IF: 3.6

2024-08-24

Diagnostics

Abstract:This study aimed to understand the dynamic changes in fibrosis and its relationship with the evaluation of post-treatment viral hepatitis using qFibrosis. A total of 158 paired pre- and post-treatment liver samples from patients with chronic hepatitis B (CHB; n = 100) and C (CHC; n = 58) were examined. qFibrosis was employed with artificial intelligence (AI) to analyze the fibrosis dynamics in the portal tract (PT), periportal (PP), midzonal, pericentral, and central vein (CV) regions. All patients with CHB achieved a virological response after 78 weeks of treatment, whereas patients with CHC achieved a sustained viral response after 24 weeks. For patients initially staged as F5/6 (Ishak system) at baseline, the post-treatment cases exhibited a significant reduction in the collagen proportionate area (CPA) (25–69%) and number of collagen strings (#string) (9–72%) across all regions. In contrast, those initially staged as F3/4 at baseline showed a similar CPA and #string trend at 24 weeks. For regression patients, 27 parameters (25 in the CV region) in patients staged as F3/4 and 15 parameters (three in the PT and 12 in the PP regions) in those staged as F5/6 showed significant differences between the CHB and CHC groups at baseline. Following successful antiviral treatment, the pre- and post-treatment liver samples provided quantitative evidence of the heterogeneity of fibrotic features. qFibrosis has the potential to provide new insights into the characteristics of fibrosis regression in both patients with CHB and CHC as early as 24 weeks after antiviral therapy.

medicine, general & internal
Title : Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy : a 2-year prospective study Running head : Liver stiffness for liver fibrosis monitoring Authors :

Xieer Liang,Qing Xie,Deming Tan,Qin Ning,Junqi Niu,Xuefan Bai,Shijun Chen,Jun Cheng,Yanyan Yu,Hao Wang,Min Xu,Guangfeng Shi,Mobin Wan,Xinyue Chen,Hong Tang,Jifang Sheng,Xiaoguang Dou,Junping Shi,Hong Ren,Maorong Wang,Hongfei Zhang,Zhiliang Gao,Chengwei Chen,Hong Ma,Yongpeng Chen,Rong Fan,Jian Sun,Jidong Jia,Jinlin Hou

2017-01-01

Abstract:Liver biopsy is not routinely performed in treated chronic hepatitis B. Liver stiffness measurement has been validated for non-invasive liver fibrosis assessment in pre-treatment chronic hepatitis B but has not been assessed for fibrosis monitoring during antiviral therapy. A cc ep te d A rt ic le This article is protected by copyright. All rights reserved. Liver stiffness was systemically monitored by Fibroscan every 6 months in a cohort of patients with hepatitis B receiving antiviral therapy and compared with liver biopsies at baseline and week 104. A total of 534 hepatitis B e antigen positive treatment-naive patients receiving telbivudine based therapy with qualified liver stiffness measurement at baseline and week 104 were analyzed, 164 of which had adequate paired liver biopsies. Liver stiffness decreased rapidly (-2.2 kPa/24 weeks) in parallel with alanine aminotransferase (ALT) from 8.6 (2.6 49.5) kPa at baseline to 6.1 (2.2 37.4) kPa at week 24. Interestingly, liver stiffness decreased slowly (-0.3 kPa/24 weeks) but continually from week 24 to week 104 (6.1 vs. 5.3 kPa, P <0.001) while ALT levels remained stable within the normal range. More importantly, liver stiffness declined significantly irrespective of baseline ALT levels and liver necro-inflammation grades. From baseline to week 104, the proportion of patients with no or mild fibrosis (Ishak, 0 2) increased from 74.4% (122/164) to 93.9% (154/164). Multivariate analysis revealed that percentage decline of 52-week liver stiffness from baseline was independently associated with 104-week liver fibrosis regression (odds ratio, 3.742; P =0.016). Early decline of 52-week liver stiffness from baseline may reflect the remission of both liver inflammation and fibrosis and was predictive of 104-week fibrosis regression in treated patients with chronic hepatitis B. Keyworks: antiviral therapy; fibrosis regression; hepatitis B; liver stiffness
Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.

X Liang,Q Xie,D Tan,Q Ning,J Niu,X Bai,S Chen,J Cheng,Y Yu,H Wang,M Xu,G Shi,M Wan,X Chen,H Tang,J Sheng,X Dou,J Shi,H Ren,M Wang,H Zhang,Z Gao,C Chen,H Ma,Y Chen,R Fan,J Sun,J Jia,J Hou

DOI: https://doi.org/10.1111/jvh.12814

2018-01-01

Journal of Viral Hepatitis

Abstract:Liver biopsy is not routinely performed in treated chronic hepatitis B. Liver stiffness measurement has been validated for noninvasive liver fibrosis assessment in pretreatment chronic hepatitis B but has not been assessed for fibrosis monitoring during antiviral therapy. Liver stiffness was systemically monitored by Fibroscan((R)) every 6months in a cohort of patients with hepatitis B receiving antiviral therapy and compared with liver biopsies at baseline and week 104. A total of 534 hepatitis B e antigen-positive treatment-naive patients receiving telbivudine-based therapy with qualified liver stiffness measurement at baseline and week 104 were analyzed, 164 of which had adequate paired liver biopsies. Liver stiffness decreased rapidly (-2.2 kPa/24weeks) in parallel with alanine aminotransferase (ALT) from 8.6 (2.6-49.5) kPa at baseline to 6.1 (2.2-37.4) kPa at week 24. Interestingly, liver stiffness decreased slowly (-0.3 kPa/24weeks) but continually from week 24 to week 104 (6.1 vs 5.3 kPa, P<.001) while ALT levels remained stable within the normal range. More importantly, liver stiffness declined significantly irrespective of baseline ALT levels and liver necroinflammation grades. From baseline to week 104, the proportion of patients with no or mild fibrosis (Ishak, 0-2) increased from 74.4% (122/164) to 93.9% (154/164). Multivariate analysis revealed that percentage decline of 52-week liver stiffness from baseline was independently associated with 104-week liver fibrosis regression (odds ratio, 3.742; P=.016). Early decline of 52-week liver stiffness from baseline may reflect the remission of both liver inflammation and fibrosis and was predictive of 104-week fibrosis regression in treated patients with chronic hepatitis B.
Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B.

Daxian Wu,Qunfang Rao,Wenqian Chen,Feiyang Ji,Zhongyang Xie,Kaizhou Huang,Er'mei Chen,Yalei Zhao,Xiaoxi Ouyang,Sainan Zhang,Zhengyi Jiang,Lingjian Zhang,Linjie Xu,Hainv Gao,Lanjuan Li

DOI: https://doi.org/10.1111/liv.13756

IF: 8.754

2018-01-01

Liver International

Abstract:Background & Aims Non-invasive assessment methods for liver fibrosis are urgently needed. The present study aimed to develop a novel diagnostic model for fibrosis staging in patients with chronic hepatitis B. MethodsResultsA cross-sectional set of 417 chronic hepatitis B patients who underwent liver biopsy was enrolled and the METAVIR score was adopted as the reference of fibrosis staging. Among thyroid hormones, only the level of free tetraiodothyronine (FT4) decreased gradually with the METAVIR fibrosis score (P<.001). FibroStage, a novel diagnosis model that incorporates data on FT4, platelets, cholinesterase, gamma-glutamyl transpeptidase, and age, was developed using the deriving set (n=219). For the diagnosis of significant fibrosis, the FibroStage model had a significantly higher area under the receiver operating curve than did the FibroIndex, Forn, and Lok models (all of P<.01) and tended to better than the fibrosis-4 (P=.0791) but comparable with the aspartate transaminase-to-platelet ratio index model (P=.1694). For the diagnosis of advanced fibrosis, FibroStage had a higher area under the receiver operating curve than did the aspartate transaminase-to-platelet ratio index, FibroIndex, Forn, and Lok models (all of P<.05) and had a comparable area under the receiver operating curve with the fibrosis-4 model (P=.2109). For the diagnosis of cirrhosis, the area under the receiver operating curve of FibroStage was higher than those of the aspartate transaminase-to-platelet ratio index, fibrosis-4, FibroIndex, and Lok (all of P<.05) models and was comparable with Forn (P=.1649). These results was validated by a validation set (n=198). ConclusionFT4 may be an indicator for fibrosis staging in chronic hepatitis B patients. FibroStage is a better model than aspartate transaminase-to-platelet ratio index, fibrosis-4, FibroIndex, Forn, and Lok for the comprehensively diagnosis of significant and advanced fibrosis and cirrhosis.
Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.

Yameng Sun,Xiaoning Wu,Jialing Zhou,Tongtong Meng,Bingqiong Wang,Shuyan Chen,Hui Liu,Tailing Wang,Xinyan Zhao,Shanshan Wu,Yuanyuan Kong,Xiaojuan Ou,Aileen Wee,Neil D. Theise,Chao Qiu,Wenhong Zhang,Fengmin Lu,Jidong Jia,Hong You

DOI: https://doi.org/10.1016/j.cgh.2020.03.001

IF: 13.576

2020-01-01

Clinical Gastroenterology and Hepatology

Abstract:BACKGROUND & AIMS: Progression of liver fibrosis still occurs in some patients with chronic hepatitis B virus (HBV) infection despite antiviral therapy. We aimed to identify risk factors for fibrosis progression in patients who received antiviral therapy. METHODS: We conducted a longitudinal study of patients with chronic HBV infection and liver biopsies collected before and after 78 weeks of anti-HBV therapy. Fibrosis progression was defined as Ishak stage increase >= 1 or as predominantly progressive classified by P-I-R system (Beijing Classification). Levels of HBV DNA and HBV RNA in blood samples were measured by real-time quantitative PCR. HBV RNA in liver tissue was detected by in situ hybridization. RESULTS: A total of 239 patients with chronic HBV infection with paired liver biopsies were included. Among the 163 patients with significant fibrosis at baseline (Ishak >= stage 3), fibrosis progressed in 22 patients (13%), was indeterminate in 24 patients (15%), and regressed in 117 patients (72%). Univariate and multivariate analyses revealed that independent risk factors for fibrosis progression were higher rate of detected HBV DNA at week 78 (odds ratio, 4.84; 95% CI, 1.30-17.98; P = .019) and alcohol intake (odds ratio, 23.84; 95% CI, 2.68-212.50; P = .004). HBV DNA was detected in blood samples from a significantly higher proportion of patients with fibrosis progression (50%) at week 78 than patients with fibrosis regression (19%) or indeterminate fibrosis (26%) (P = .015), despite low viremia (20-200 IU/mL) in all groups. The decrease of serum HBV RNA from baseline in the fibrosis regression group was larger than that in the fibrosis progression group. CONCLUSIONS: In a longitudinal study of patients with chronic HBV infection, we associated liver fibrosis progression at week 78 of treatment with higher rates of detected HBV DNA. We propose that a low level of residual HBV may still promote fibrosis progression, and that patients' levels of HBV DNA should be carefully monitored.
Systematic Review with Meta-Analysis: the Diagnostic Accuracy of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B

Y. Li,Yong Huang,Z.-Z. Wang,Zhirong Yang,Feng Sun,Siyan Zhan,Xue-En Liu,Hongqing Zhuang

DOI: https://doi.org/10.1111/apt.13488

IF: 9.524

2015-01-01

Alimentary Pharmacology & Therapeutics

Abstract:Background Transient elastography is a non-invasive method for staging liver fibrosis. The meta-analysis using the hierarchical models to evaluate the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B was rarely reported. Aim A meta-analysis using the hierarchical models was performed to assess transient elastography for diagnosing and stage liver fibrosis in patients with chronic hepatitis B. Methods Electronic databases were searched and studies were identified to assess the diagnostic accuracy of transient elastography in CHB patients for staging fibrosis F ≥ 2, F ≥ 3 and F = 4 with liver biopsy as a reference standard. The hierarchical summary receiver operating characteristic curve and the bivariate models were performed to evaluate the diagnostic accuracy of transient elastography, and meta-regression analyses were performed to explore the heterogeneity. The quality Assessment of Diagnostic Accuracy Studies-2 tool was used to assess the quality of studies. Results Twenty-seven studies with a total of 4386 patients were included in the meta-analysis. The summary sensitivity of transient elastography for staging fibrosis F ≥ 2, F ≥ 3 and F = 4 was 0.806 (95% CI, 0.756–0.847), 0.819 (95% CI, 0.748–0.874) and 0.863 (95% CI, 0.818–0.898), respectively, and the summary specificity was 0.824 (95% CI, 0.761–0.873), 0.866 (95% CI, 0.824–0.899) and 0.875 (95% CI, 0.840–0.903), respectively. The corresponding area under the summary receiver operating characteristic curve was 0.88 (95% CI, 0.85–0.91), 0.91 (95% CI, 0.88–0.93) and 0.93 (95% CI, 0.91–0.95), respectively. Meta-regression showed that patient age contributed to heterogeneity. Conclusions Transient elastography performs well to diagnose liver fibrosis in patients with chronic hepatitis B, which may reduce the use of liver biopsy.
Transient Elastography Compared to Serum Markers to Predict Liver Fibrosis in a Cohort of Chinese Patients with Chronic Hepatitis B

Jidong Jia,Jinlin Hou,Huiguo Ding,Guofeng Chen,Qing Xie,Yuming Wang,Minde Zeng,Jingmin Zhao,Tailing Wang,Xiqi Hu,D. Schuppan

DOI: https://doi.org/10.1111/jgh.12840

2014-01-01

Journal of Gastroenterology and Hepatology

Abstract:Background and AimLiver stiffness measurement (LSM) using transient elastography (FibroScan) is a useful tool to assess fibrosis in various chronic liver diseases. However, studies were mainly performed in Western countries and largely focused on chronic hepatitis C (CHC). We therefore carried out a multicenter study to validate the accuracy of LSM in the assessment of liver fibrosis in a large cohort of Chinese patients with chronic hepatitis B (CHB).MethodsWe compared LSM results to histological staging and serum fibrosis markers (five direct markers, APRI and FIB-4) using Spearman correlation analysis and area under receiver operating characteristic (ROC) curves (AUROCs).ResultsFour hundred sixty-nine patients were enrolled and eligible for statistical analysis. LSM in F0 to F4 was 5.51.7, 5.8 +/- 2.2, 7.6 +/- 3.4, 14.5 +/- 10.8, and 22.3 +/- 13.6kPa, respectively (correlation with fibrosis stage r=0.522, P<0.001). AUROC for LSM to correctly allocate patients to histological fibrosis stage F2, F3, and F4 was 0.82, 0.88, and 0.90, respectively. LSM outperformed serum fibrosis markers for detection of fibrosis F2 and F4. Patients with ALT levels 1-5x and >5x the upper limit of normal values had significantly higher stiffness values than stage-matched patients with normal alanine aminotransferase.ConclusionTransient elastography is a reliable noninvasive technique to predict significant liver fibrosis in Chinese patients with CHB, being superior to current biomarker panels. However, enhanced inflammatory activity can lead to elevated stiffness values unrelated to histological fibrosis stage.
Accuracy of Transient Elastography in the Assessment of Chronic Hepatitis C-Related Liver Cirrhosis

Hai-Yan Ying,Lun-Gen Lu,Da-Dao Jing,Xiu-Shi Ni

DOI: https://doi.org/10.25011/cim.v39i5.27147

2016-01-01

Abstract:PURPOSE:Staging liver cirrhosis is essential for the management of chronic hepatitis C (CHC). The current meta-analysis evaluated the accuracy of transient elastography for detecting liver cirrhosis in patients with CHC.METHODS:Either prospective or retrospective studies, including cohort and cross sectional studies, in patients diagnosed with chronic hepatitis C, as assessed by transient elastography, were searched from Medline, Cochrane, EMBASE, and Google Scholar databases until March 3, 2015, using the terms "transient elastography, chronic hepatitis C and liver cirrhosis". The primary outcome analyzed was the diagnostic performance, which included sensitivity, specificity, diagnostic odds ratio and area under the receiver-operating characteristic (ROC) curve.RESULTS:Data from 24 articles included in the meta-analysis demonstrated high sensitivity (84%) and specificity (90%) of transient elastography (TE) for assessing liver cirrhosis patients with HCV. Subgroup analysis of patients by underlying diseases revealed a sensitivity and specificity of 91% and 92% (HCV alone), 100% and 75% (HCV-liver transplant), 83.6% and 89.7% (HIV/HCV co-infection) and 97.1% and 90.7% (recurrent CHC after liver transplantation). The pooled diagnostic odds ratio was 61.57 (95% CI, 39.5 - 96.00) and the area under the summary ROC curves was 0.952 ± 0.008, suggesting high diagnostic accuracy of TE.CONCLUSION:Transient elastography can accurately predict liver cirrhosis in patients with hepatitis C, with a sensitivity and specificity of 84% and 90%, respectively. The present results further validate the utility of TE in staging liver cirrhosis in chronic HCV infections.
Accuracy of transient elastography in assessing fibrosis at diagnosis in individuals with autoimmune liver disease.

Yue Shen,Hong Chen,Sheng-Di Wu,Wei Jiang

DOI: https://doi.org/10.1016/j.jhep.2022.08.013

IF: 25.7

2022-01-01

Journal of Hepatology

Abstract:Recently, this Journal published a large, multi-center, longitudinal cohort study by Corpechot et al., which validated the prognostic value of baseline liver stiffness (LS) by vibration-controlled transient elastography (VCTE) in individuals with primary biliary cholangitis (PBC). LS also improved the prognostic performance of established biochemical markers of treatment response.1
Liver Fibrosis with Two-dimensional US Shear-Wave Elastography in Participants with Chronic Hepatitis B: A Prospective Multicenter Study.

Yongyan Gao,Jian Zheng,Ping Liang,Minghui Tong,Jiabing Wang,Changjun Wu,Xin He,Changzhu Lin,Shumei Zhang,Liping Huang,Tian'an Jiang,Chao Cheng,Fankun Meng,Xiaojie Mu,Yongping Lu,Yanyan Li,Hong Ai,Xudong Qiao,Xiao-Yan Xie,Wei Wang,Li-ping Yin,Yi-yun Wu,Rongqin Zheng

DOI: https://doi.org/10.1148/radiol.2018172479

IF: 19.7

2018-01-01

Radiology

Abstract:Purpose: To investigate the diagnostic performance of two-dimensional (2D) shear-wave elastography (SWE) in chronic hepatitis B. Materials and Methods: This prospective multicenter study from January 2015 to January 2016 was conducted at 12 hospitals and included 654 participants with chronic hepatitis B who had undergone liver biopsy and 2D SWE examination. Participants were divided into chronic infection and chronic hepatitis groups. The diagnostic performance of 2D SWE was compared with the aspartate amino transferase-to-platelet ratio index (APRI), the Fibrosis-4 index (FIB-4), and transient elastography (TE) by using a DeLong test and was also compared between two subgroups. Dual cutoff values for cirrhosis were determined with multilevel likelihood ratio analysis. Results: Overall, 402 participants with chronic hepatitis B were enrolled (154 with chronic infection and 248 with chronic hepatitis). The areas under the receiver operating characteristic curve of 2D SWE (0.87; 95% confidence interval [CI]: 0.83, 0.90) were higher than those of TE (0.80; 95% CI: 0.68, 0.88), APRI (0.70; 95% CI: 0.65, 0.74), and FIB-4 (0.73; 95% CI: 0.69, 0.78) in cirrhosis. The high area under the receiver operating characteristic curve (0.92; 95% CI: 0.87, 0.96) was achieved in the chronic infection group and was significantly higher than that of the chronic hepatitis group (0.84; 95% CI: 0.78, 0.88; P = .017). Dual cutoff values with the likelihood ratios below 0.1 and above 10 (8.4 kPa and 11.0 kPa to rule out and rule in a diagnosis of cirrhosis, respectively) were effectively determined in chronic infection; a total of 81.2% (125 of 154) participants with cirrhosis were definitively diagnosed. Conclusion: The performance of two-dimensional (2D) shear-wave elastography (SWE) was higher than that of other noninvasive methods. 2D SWE was most effective in ruling in and ruling out cirrhosis in participants with chronic infection, which may prompt antiviral treatment. (c) RSNA, 2018
Multicenter Prospective Study to Validate a New Transient Elastography Device for Staging Liver Fibrosis in Patients with Chronic Hepatitis B

Wei Jia Duan,Xiao Zhong Wang,An Lin Ma,Jia Shang,Yue Min Nan,Zhi Liang Gao,Hong Tang,Qing Chun Fu,Qing Xie,Qing Mao,Jun Qi Niu,Tao Han,Jun Li,Ying Han,Jian Biao Cao,Yuan,Xiao Yan Shi,Fu Dong Lv,Tai Ling Wang,Hong Ma,Hong You,Xiao Juan Ou,Ji Dong Jia

DOI: https://doi.org/10.1111/1751-2980.12924

2020-01-01

Journal of Digestive Diseases

Abstract:ObjectivesTo validate the operational and diagnostic performances of a new device for transient elastography (TE), FibroTouch, for liver fibrosis in patients with chronic hepatitis B (CHB).MethodsIn this prospective multicenter study, adult patients with CHB and valid liver pathological results were recruited to validate the operational and diagnostic performance of a TE device by FibroTouch for staging liver fibrosis.ResultsIn total, 517 patients with histologically proven CHB were enrolled. All had achieved at least 10 successful liver stiffness measurements (LSM), resulting in a success rate of 99.1% and reliable evaluations of 95.2%. Altogether 412 patients were included to analyze the diagnostic performance of FibroTouch. The area under the receiver operating characteristic curve for the LSM was 0.846 (95% confidence interval [CI] 0.808‐0.880) for fibrosis stage ≥ F1, 0.850 (95% CI 0.811‐0.883) for ≥ F2, 0.908 (95% CI 0.876‐0.934) for ≥ F3 and 0.874 (95% CI 0.836‐0.903) for F4. The diagnostic accuracy of LSM was superior to that of gamma‐glutamyl transpeptidase‐to‐platelet ratio (GPR), aminotransferase‐to‐platelet ratio index (APRI), or fibrosis index based on 4 factors (FIB‐4) index in staging fibrosis F2‐F4 (P = 0.007 to < 0.0001). Optimal LSM cut‐off values for diagnosing fibrosis stage ≥ F1, ≥ F2, ≥ F3, and F4 were 5.5 kPa, 7.85 kPa, 10.0 kPa, and 12.7 kPa, respectively.ConclusionFibroTouch has a high success rate and good reliability in staging liver fibrosis in patients with CHB.
New Classification Of Liver Biopsy Assessment For Fibrosis In Chronic Hepatitis B Patients Before And After Treatment

Yameng Sun,Jialing Zhou,Lin Wang,Xiaoning Wu,Yongpeng Chen,Hongxin Piao,Lungen Lu,Wei Jiang,Youqing Xu,Bo Feng,Yuemin Nan,Wen Xie,Guofeng Chen,Huanwei Zheng,Hai Li,Huiguo Ding,Hui Liu,Fudong Lv,Chen Shao,Tailing Wang,Xiaojuan Ou,Bingqiong Wang,Shuyan Chen,Aileen Wee,Neil D. Theise,Hong You,Jidong Jia

DOI: https://doi.org/10.1002/hep.29009

IF: 17.298

2017-01-01

Hepatology

Abstract:Liver fibrosis is the net result of dynamic changes between fibrogenesis and fibrolysis. Evidence has shown that antiviral therapy can reverse liver fibrosis or even early cirrhosis caused by hepatitis B virus. However, current evaluation systems mainly focus on the severity of, but not the dynamic changes in, fibrosis. Here, we propose a new classification to evaluate the dynamic changes in the quality of fibrosis, namely: predominantly progressive (thick/broad/loose/pale septa with inflammation); predominately regressive (delicate/thin/dense/splitting septa); and indeterminate, which displayed an overall balance between progressive and regressive scarring. Then, we used this classification to evaluate 71 paired liver biopsies of chronic hepatitis B patients before and after entecavir-based therapy for 78 weeks. Progressive, indeterminate, and regressive were observed in 58%, 29%, and 13% of patients before treatment versus in 11%, 11%, and 78% after treatment. Of the 55 patients who showed predominantly regressive changes on posttreatment liver biopsy, 29 cases (53%) had fibrosis improvement of at least one Ishak stage, and, more interestingly, 25 cases (45%) had significant improvement in terms of Laennec substage, collagen percentage area, and liver stiffness despite remaining in the same Ishak stage. Conclusion: This new classification highlights the importance of assessing and identifying the dynamic changes in the quality of fibrosis, especially relevant in the era of antiviral therapy.
High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy

Xiujuan Chang,Yinying Li,Chao Sun,Xiaodong Li,Wenjuan Du,Qinghua Shang,Laicheng Song,Qinghua Long,Qin Li,Huabao Liu,Jing Wang,Zujiang Yu,Jiang Li,Guangming Xiao,Li Li,Liang Chen,Lin Tan,Yongping Chen,Yongping Yang

DOI: https://doi.org/10.1007/s00535-023-01970-3

Abstract:Background: Progressive hepatic fibrosis leads to hepatocellular carcinoma (HCC) and decompensated cirrhosis. The aim of this study was to identify the high-risk population for progressive hepatic fibrosis and the incidence of HCC and decompensated cirrhosis in chronic hepatitis B (CHB) patients with antiviral therapy. Methods: The data came from a multicenter, center-randomized, double-blind clinical trial that analyzed only patients in the ETV-treated arm. There was 156 hepatitis B e antigen (HBeAg)-positive and 135 HBeAg-negative patients in 14 institutions. The primary endpoint was fibrosis reversal on 72-week Entecavir (ETV) treatment. The 7-year cumulative incidence of HCC and decompensated cirrhosis were analyzed. Multivariate logistic and LASSO regression analyses were used to screen variables associated with fibrosis reversal. Results: 86/156 (55%) HBeAg-positive and 58/135 (43%) HBeAg-negative patients achieved fibrosis reversal on 72-week ETV treatment. Average age was 43 years, 203 (69.8%) was male, and 144 (49.5%) patients had cirrhosis. Age ≥ 40 years (OR: 0.46, 95% CI 0.23-0.93) and HBcrAg ≥ 8.23 log U/ml (OR: 2.72, 95% CI 1.33-5.54) in HBeAg-positive patients and HBV genotype C (OR: 0.44, 95% CI 0.21-0.97) in HBeAg-negative patients were independent factors of fibrosis reversal. It was confirmed in patients with cirrhosis. After 7-year ETV treatment, seven (4.5%) HBeAg-positive patients occurred HCC or decompensated cirrhosis, including four patients with age ≥ 40 years and six with HBcrAg 8.23log U/ml, while twelve (8.9%) HBeAg-negative patients occurred, including eleven with HBV genotype C. Conclusions: HBeAg-positive patients with a low HBcrAg level or old age, and HBeAg-negative patients with HBV genotype C tended to develop progressive hepatic fibrosis and had a high incidence of HCC and decompensated cirrhosis, even on ETV treatment.
[Validation of Transient Elastography (fibroscan) in Assessment of Hepatic Fibrosis in Autoimmune Hepatitis].

Qi-xia Wang,Lei Shen,De-kai Qiu,Han Bao,Xiao-yu Chen,Min-de Zeng,Yi-min Mao,Xiong Ma

DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2011.10.015

2011-01-01

Abstract:OBJECTIVE:To validate transient elastography (Fibroscan) in assessment of hepatic fibrosis in autoimmune hepatitis (AIH).METHODS:Liver stiffness was assessed using Fibroscan in totally 30 patients with AIH. We compared the results of Fibroscan with the Scheuer fibrosis stage in liver biopsy in each patient.RESULTS:4 patients were shown as liver fibrosis stage S0, 6 as S1, 5 as S2, 11 as S3 and 4 as S4. Failure of the Fibroscan measurement occurred in 1 case (3.3%) because of her increased body mass index (BMI). The stiffness of Fibroscan was significantly correlated with the liver biopsy fibrosis stage (r = 0.801, P less than 0.001). The liver stiffnesses between mild and moderate fibrosis (S0-2) and advanced fibrosis (S3-4) were significantly different (t = -3.937, P = 0.001).CONCLUSION:Transient elastography (Fibroscan) is a promising non-invasive method for detection of fibrosis in patients with autoimmune hepatitis. Its use for the follow up and management of these patients and should be evaluated further.
Prognostic Effects of Liver Fibrosis and Steatosis Determined Using Transient Elastography in Patients with Chronic Hepatitis B or C

Chun-Li Wang,Chien-Hao Huang,Victor Chien-Chia Wu,Chia-Ling Wu,Yu-Tung Huang,Shang-Hung Chang

DOI: https://doi.org/10.1007/s10620-023-07943-z

Abstract:Background: The prognostic effects of liver fibrosis and steatosis in patients with chronic hepatitis B or C are unclear. We investigated the prognostic effects of liver fibrosis and steatosis determined through transient elastography (TE) in patients with chronic hepatitis B or C. Methods: This retrospective cohort study enrolled 5528 patients with chronic hepatitis B or C who received TE. Multivariate Cox regression was used to evaluate the associations between fibrosis and steatosis grades and the occurrence of hepatic-related events, cardiovascular events, and mortality. Liver stiffness measurements of ≥ 7.1, ≥ 9.5, and ≥ 12.5 kPa were considered to indicate significant fibrosis (≥ F2), advanced fibrosis (≥ F3), and cirrhosis (≥ F4), and controlled attenuation parameters of ≥ 230 and ≥ 264 dB/m were considered to indicate mild (S1) and moderate-to-severe (S2-S3) steatosis, respectively. Results: During a median follow-up of 3.1 years, 489 patients died, 814 had hepatic-related events, and 209 had cardiovascular events. The incidences of these outcomes were lowest among individuals with no- or mild-fibrosis (F0-F1), and increased with fibrosis severity. The incidence of adverse outcomes was highest among patients without steatosis (S0) and lowest among those with moderate-to-severe steatosis. Adjusted models indicated that F2, F3, and F4 were independent risk factors and that moderate-to-severe steatosis was a favorable marker for hepatic-related events. Cirrhosis was an independent factor for mortality. Conclusions: According to TE, increasing fibrosis grades and absence of steatosis were associated with higher risks of hepatic-related events, whereas cirrhosis was a risk factor for mortality in patients with chronic hepatitis B or C.
Longitudinal Monitoring of Liver Stiffness by Acoustic Radiation Force Impulse Imaging in Patients with Chronic Hepatitis B Receiving Entecavir.

Sheng-Di Wu,Hong Ding,Li-Li Liu,Yuan Zhuang,Yun Liu,Li-Sha Cheng,Si-Qi Wang,Yu-Jen Tseng,Ji-Yao Wang,Wei Jiang

DOI: https://doi.org/10.1016/j.clinre.2017.08.006

IF: 3.189

2017-01-01

Clinics and Research in Hepatology and Gastroenterology

Abstract:Background: Acoustic radiation force impulse (ARFI) imaging measures liver stiffness (LS), which significantly correlates with the stage of liver fibrosis in treatment-naive patients with chronic hepatitis B (CHB). Aim: We aimed to prospectively assess the clinical usefulness of ARFI during long-term antiviral therapy in CHB. Method: Seventy-one CHB patients were consecutively recruited and paired liver biopsies were performed in 27 patients. LS was assessed by ARFI semiannually during entecavir therapy. Results: LS gradually decreased with treatment and continued to decrease after normalization of alanine aminotransaminase. Overall, 97.2% patients achieved improvement of LS, whereas 19.7% patients had more than 30% reduction in LS values between baseline and week 104. Multivariate linear regression analysis showed that the degree of LS reduction significantly correlated with the baseline levels of LS value, platelet and cholmesterase. In the 27 patients who underwent paired liver biopsies, LS significantly correlated with stage of fibrosis and inflammatory grade at baseline. LS values decreased more significantly in patients with fibrosis regression than those with static histological fibrosis. Conclusion: In CHB patients, LS assessed by ARFI was gradually reduced during antiviral therapy. Longitudinal monitoring of LS may be a promising noninvasive assessment of fibrosis regression during long-term antiviral therapy in CHB. Further large sample studies are needed. (C) 2017 Elsevier Masson SAS. All rights reserved.
Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography

Jingxin Zhao,Fei Zhai,Jun Cheng,Qiong He,Jianwen Luo,Xueping Yang,Jinhua Shao,Huichun Xing

DOI: https://doi.org/10.1371/journal.pone.0170073

IF: 3.7

2017-01-01

PLoS ONE

Abstract:Transient elastography quantifies the propagation of a mechanically generated shear wave within a soft tissue, which can be used to characterize the elasticity and viscosity parameters of the tissue. The aim of our study was to combine numerical simulation and clinical assessment to define a viscoelastic index of liver tissue to improve the quality of early diagnosis of liver fibrosis. This is clinically relevant, as early fibrosis is reversible. We developed an idealized two-dimensional axisymmetric finite element model of the liver to evaluate the effects of different viscoelastic values on the propagation characteristics of the shear wave. The diagnostic value of the identified viscoelastic index was verified against the clinical data of 99 patients who had undergone biopsy and routine blood tests for staging of liver disease resulting from chronic hepatitis B infection. Liver stiffness measurement (LSM) and the shear wave attenuation fitting coefficient (AFC) were calculated from the ultrasound data obtained by performing transient elastography. Receiver operating curve analysis was used to evaluate the reliability and diagnostic accuracy of LSM and AFC. Compared to LSM, the AFC provided a higher diagnostic accuracy to differentiate early stages of liver fibrosis, namely F1 and F2 stages, with an overall specificity of 81.48%, sensitivity of 83.33% and diagnostic accuracy of 81.82%. AFC was influenced by the level of LSM, ALT. However, there are no correlation between AFC and Age, BMI, TBIL or DBIL. Quantification of the viscoelasticity of liver tissue provides reliable measurement to identify and differentiate early stages of liver fibrosis.

Can Transient Elastography Predict Fibrosis Regression in Patients with Chronic Hepatitis B During Long-Term Antiviral Therapy?

The Value of Ultrasonic Elastographic Parameters in the Evaluation of Chronic Hepatitis B Liver Fibrosis

A New Visual Transient Elastography Technique for Grading Liver Fibrosis in Patients with Chronic Hepatitis B.

Longitudinal Monitoring of Liver Fibrosis Status by Transient Elastography in Chronic Hepatitis B Patients During Long-Term Entecavir Treatment.

AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response

Title : Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy : a 2-year prospective study Running head : Liver stiffness for liver fibrosis monitoring Authors :

Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.

Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B.

Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.

Systematic Review with Meta-Analysis: the Diagnostic Accuracy of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B

Transient Elastography Compared to Serum Markers to Predict Liver Fibrosis in a Cohort of Chinese Patients with Chronic Hepatitis B

Accuracy of Transient Elastography in the Assessment of Chronic Hepatitis C-Related Liver Cirrhosis

Accuracy of transient elastography in assessing fibrosis at diagnosis in individuals with autoimmune liver disease.

Liver Fibrosis with Two-dimensional US Shear-Wave Elastography in Participants with Chronic Hepatitis B: A Prospective Multicenter Study.

Multicenter Prospective Study to Validate a New Transient Elastography Device for Staging Liver Fibrosis in Patients with Chronic Hepatitis B

New Classification Of Liver Biopsy Assessment For Fibrosis In Chronic Hepatitis B Patients Before And After Treatment

High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy

[Validation of Transient Elastography (fibroscan) in Assessment of Hepatic Fibrosis in Autoimmune Hepatitis].

Prognostic Effects of Liver Fibrosis and Steatosis Determined Using Transient Elastography in Patients with Chronic Hepatitis B or C

Longitudinal Monitoring of Liver Stiffness by Acoustic Radiation Force Impulse Imaging in Patients with Chronic Hepatitis B Receiving Entecavir.

Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography